LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

LLY

993.81

+1.76%↑

JNJ

224.78

-0.46%↓

ABBV

205.21

-0.98%↓

UNH

368.37

+0.61%↑

AZN

185.24

+2.6%↑

Home・Elenco Azioni・Beam Therapeutics Inc

Beam Therapeutics Inc

Chiusa

SettoreSettore sanitario

29.31 -2.95

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

28.48

Massimo

30.52

Metriche Chiave
By Trading Economics
Entrata	357M 244M
Vendite	104M 114M
Margine di Profitto	214.091
Dipendenti	511
EBITDA	368M 261M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+60.84% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	122M 3B
Apertura precedente	32.26
Chiusura precedente	29.31

Notizie sul Sentiment di mercato

By Acuity

23%

77%

76 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

16.225 / 20.17 Supporto e resistenza

Beam Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2026, 23:43 UTC

Principali Notizie su Eventi

New Zealand's Unemployment Rate Falls in 1Q

5 mag 2026, 23:20 UTC

Azioni calde

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 mag 2026, 21:48 UTC

Utili

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 mag 2026, 21:05 UTC

Acquisizioni, Fusioni, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 mag 2026, 00:00 UTC

Discorsi di Mercato

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 mag 2026, 22:26 UTC

Discorsi di Mercato

AMD Data-Center Business Continues to Surge -- Market Talk

5 mag 2026, 22:20 UTC

Discorsi di Mercato

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 mag 2026, 22:08 UTC

Utili

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 mag 2026, 22:07 UTC

Utili

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 mag 2026, 21:48 UTC

Utili

Pan American Silver 1Q Rev $1.2B >PAAS

5 mag 2026, 21:42 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:38 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:30 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:29 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:26 UTC

Utili

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q EPS 39c >ALC.EB

5 mag 2026, 21:25 UTC

Utili

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 mag 2026, 21:24 UTC

Utili

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 mag 2026, 21:18 UTC

Utili

Mistras Backs 2026 Rev $730M-$750M >MG

5 mag 2026, 21:17 UTC

Utili

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 mag 2026, 21:15 UTC

Utili

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 mag 2026, 21:12 UTC

Utili

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 mag 2026, 21:11 UTC

Utili

SSR Mining 1Q Rev $581.8M >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 mag 2026, 21:10 UTC

Utili

SSR Mining 1Q EPS $1.16 >SSRM

5 mag 2026, 21:08 UTC

Utili

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 mag 2026, 21:01 UTC

Utili

Intact Financial 1Q EPS C$4.12 >IFC.T

5 mag 2026, 21:01 UTC

Azioni calde

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Confronto tra pari

Modifica del prezzo

Beam Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

60.84% in crescita

Previsioni per 12 mesi

Media 48.38 USD 60.84%

Alto 80 USD

Basso 24.18 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Beam Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Beam Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

16.225 / 20.17Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

76 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.